MedTrace Logo

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-02-08

Study results available
· View outcomes & findings →

Summary

The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

Conditions

Interventions

DRUG

Ketamine

A single dose of intranasal ketamine up to 50 mg

DRUG

placebo

Single dose of saline intranasal

Sponsors & Collaborators

  • James Murrough

    lead OTHER

Principal Investigators

  • James W Murrough, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304147 on ClinicalTrials.gov